Tandem Diabetes Care
Open
$16.52
Prev. Close
$16.54
High
$16.61
Low
$16.43
Market Snapshot
$1.13B
-12.0
-1.46
$940.2M
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. The company is headquartered in San Diego, California and currently employs 2,500 full-time employees. The company went IPO on 2013-11-13. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.
Tandem Diabetes Care continues to innovate in diabetes management technology, reinforcing its position as a leader in insulin delivery systems amidst fluctuating market conditions.
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. The company is headquartered in San Diego, California and currently employs 2,500 full-time employees. The company went IPO on 2013-11-13. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.
Recently from Cashu
Tandem Diabetes Care Strengthens Governance and Strategic Outlook with Shareholder Support
Tandem Diabetes Care (Ticker: TNDM) is taking significant steps toward enhancing its corporate governance and strategic outlook. In a recent shareholder meeting, the company receives strong support fr…
Tandem Diabetes Care: Leading Innovation in Diabetes Management and Market Growth
Tandem Diabetes Care: Innovating Diabetes Management Amid Market Optimism Tandem Diabetes Care Inc. stands out in the healthcare technology landscape for its commitment to diabetes management innovati…
Tandem Diabetes Care Enhances Market Impact with Innovative Insulin Delivery Technologies
Tandem Diabetes Care Innovations Propel Market Influence Tandem Diabetes Care continues to solidify its position in the diabetes management industry with innovative advancements in insulin delivery te…
Tandem Diabetes Care Advances Continuous Glucose Monitoring for Enhanced Patient Outcomes
Tandem Diabetes Care Innovates in Continuous Glucose Monitoring Tandem Diabetes Care is making significant strides in the diabetes management industry, particularly with its advancements in continuous…